4-(3,3-dimethylbutanoyl)-2-fluorobenzonitrile | 1395795-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3,3-dimethylbutanoyl)-2-fluorobenzonitrile
• 英文别名: 4-(3,3-Dimethylbutanoyl)-2-fluorobenzonitrile
• CAS: 1395795-36-4
• 化学式: C₁₃H₁₄FNO
• 分子量: 219.259
• InChiKey: DOQGPMJPHBDMIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,3-dimethylbutanoyl)-2-fluorobenzonitrile 在 sodium tetrahydroborate 、 potassium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 26.5h， 生成 2-(3-bromophenoxy)-4-(3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzonitrile
  参考文献：
  名称：

  Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK)

  摘要：

  Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in rational-design, structure-supported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit binding mode. Lead optimization, aided by X-ray crystallography, led to picomolar inhibitors of both Streptococcus pneumoniae and Staphylococcus aureus TMK. MICs < 1 mu g/mL were achieved against methicillin-resistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant. Enterococcus (VRE). Log D adjustments yielded single diastereomers 14 (TK-666) and 46, showing a broad antibacterial spectrum against Gram-positive bacteria and excellent selectivity against the human thymidylate kinase ortholog.

  DOI：

  10.1021/jm3011806
• 作为产物：
  描述：

  3,3-二甲基丁酰氯 、 bromozinc(1+),2-fluorobenzene-4-ide-1-carbonitrile 在 四(三苯基膦)钯 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以85%的产率得到4-(3,3-dimethylbutanoyl)-2-fluorobenzonitrile
  参考文献：
  名称：

  Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK)

  摘要：

  Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in rational-design, structure-supported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit binding mode. Lead optimization, aided by X-ray crystallography, led to picomolar inhibitors of both Streptococcus pneumoniae and Staphylococcus aureus TMK. MICs < 1 mu g/mL were achieved against methicillin-resistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant. Enterococcus (VRE). Log D adjustments yielded single diastereomers 14 (TK-666) and 46, showing a broad antibacterial spectrum against Gram-positive bacteria and excellent selectivity against the human thymidylate kinase ortholog.

  DOI：

  10.1021/jm3011806

文献信息

• Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK)
  作者：Gabriel Martínez-Botella、John N. Breen、James E. S. Duffy、Jacques Dumas、Bolin Geng、Ian K. Gowers、Oluyinka M. Green、Satenig Guler、Martin F. Hentemann、Felix A. Hernandez-Juan、Diane Joseph-McCarthy、Sameer Kawatkar、Nicholas A. Larsen、Ovadia Lazari、James T. Loch、Jacqueline A. Macritchie、Andrew R. McKenzie、Joseph V. Newman、Nelson B. Olivier、Linda G. Otterson、Andrew P. Owens、Jon Read、David W. Sheppard、Thomas A. Keating

  DOI：10.1021/jm3011806

  日期：2012.11.26

  Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in rational-design, structure-supported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit binding mode. Lead optimization, aided by X-ray crystallography, led to picomolar inhibitors of both Streptococcus pneumoniae and Staphylococcus aureus TMK. MICs < 1 mu g/mL were achieved against methicillin-resistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant. Enterococcus (VRE). Log D adjustments yielded single diastereomers 14 (TK-666) and 46, showing a broad antibacterial spectrum against Gram-positive bacteria and excellent selectivity against the human thymidylate kinase ortholog.